BioSpace News Archive

Aegle Therapeutics Corporation, a first-in-class biotechnology company developing extracellular vesicles as therapy, today announced that the Company has been awarded a grant by the U.S.

IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSXV: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced an update on their NSERC-funded partnership with the

Pharm-Olam, a global mid-sized clinical research organization (CRO), has been selected by the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response, to join their Clinical Studies Network.

Johnson & Johnson (NYSE: JNJ) (the Company) today announced the European Commission (EC), acting on behalf of the European Union (EU) Member States, has approved an Advance Purchase Agreement in which the Janssen Pharmaceutical Companies will supply 200 million doses of its COVID-19 vaccine candidate to EU Member States following approval or authorization from regulators

SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced preliminary unaudited revenue for the three and nine months ended September 30, 2020.

Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) (“Avricore” or the “Company”) has achieved significant milestones in completing due diligence, technical reviews and initial connectivity between its real-time data reporting platform, HealthTab™ and a leading point-of-care device

P ortfolio includes VIP152, a highly selective PTEFb /CDK9 inhibitor with encouraging Phase 1 monotherapy activity , including complete responses in DH-DLBCL Vincera intends to pursue multiple accelerated approval opportunities in M YC - and MCL1- driven cancers Preclinical bioconjugation platform designed to overcome limitations of small - molecule and antibody - drug conjugates use to treat cancer SANTA CLARA, Calif., Oct. 08, 2020 (GLOBE NEWSWIRE)

Almirall, S.A. (ALM), a global biopharmaceutical company focused on skin health, and University of Dundee, a top-ranked university in the UK for biological sciences, announced today a research collaboration agreement with the aim to identify and develop a novel class of medicines that target and degrade disease-causing proteins

Skin tightening is one the most popular esthetic treatments. Several skin tightening techniques have been developed.

Evotec SE announced that the Company has received a US$ 6 m payment from Bristol Myers Squibb Company following the decision to expand the portfolio by another drug discovery project.